Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHY906 with Saltz regimen in advanced colorectal cancer
NCT00036517Phase 2Terminated
- Sponsor
- PhytoCeutica
- Start
- Feb 2002
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing PHY906 + Saltz with Placebo + Saltz (2 arms). Primary endpoints: Safety and Tolerability of PHY906 with Saltz Regimen and Minimum Effective Dose of PHY906. Started Feb 2002; status: terminated.
02
Drugs
PHY906
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00036517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036517.